| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | ViroGates A/S: ViroGates announces its interim report for Q1-Q3 2026 | 406 | GlobeNewswire (Europe) | Company Announcement no. 10/2026 (November 05, 2026)
Revenue up 75%, driven largely by U.S. partner orders in Q2
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology... ► Artikel lesen | |
| 20.08. | ViroGates A/S: ViroGates announces its half-year report for H1 2026 | 264 | GlobeNewswire (Europe) | Company Announcement no. 9/2026 (August 20, 2026)
Revenue grew significantly compared to H1 2025, driven largely by U.S. partner building up stock for market roll-out
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 03.08. | ViroGates A/S: ViroGates announces changes to its commercial organization | 273 | GlobeNewswire (Europe) | Company Announcement no. 6/2026 (August 03, 2026)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation at health clinics... ► Artikel lesen | |
| 07.05. | ViroGates A/S: ViroGates announces its Interim Report for Q1-2026 | 269 | GlobeNewswire (Europe) | Company Announcement no. 5/2026 (May 07, 2026 at 13:12:00 CEST)
Revenue increased 8% Y-o-Y in Q1 to DKK 1.3 million, and net loss decreased by 6% to DKK 2.6 million
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 23.04. | ViroGates A/S: Resolutions from the Annual General Meeting of ViroGates A/S | 221 | GlobeNewswire (Europe) | Company Announcement no. 4/2026 (April 23, 2026 at 20:15:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring... ► Artikel lesen | |
| 08.04. | ViroGates A/S: ViroGates submits its De Novo application to the U.S. FDA for suPARnostic TurbiLatex | 447 | GlobeNewswire (Europe) | Company Announcement no. 3/2026 (April 08, 2026 at 22:37:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 26.03. | ViroGates A/S: ViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues | 849 | GlobeNewswire (Europe) | Company Announcement no. 1/2026 (March 26, 2026 at 15:10:00 CET)
Inside information
BIRKERØD, DENMARK ViroGates A/S ("ViroGates" or "Company"), a medical technology company developing blood tests for... ► Artikel lesen | |
| 12.12.25 | ViroGates A/S: ViroGates announces financial guidance for 2026 | 305 | GlobeNewswire (Europe) | Company Announcement no. 22/2025 (December 12, 2025)
BIRKERØD, DENMARK-ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 28.11.25 | ViroGates A/S: ViroGates' capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled | 467 | GlobeNewswire (Europe) | Company Announcement no. 21/2025 (November 28, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company") announces that the capital raise of approximately DKK 19.3 million and the issue... ► Artikel lesen | |
| 26.11.25 | ViroGates A/S - increase | 336 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as of 28 November 2025. New shares are issued due to a directed issue of new shares.
Name:
ViroGates
ISIN:
DK0061030574
Short... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |